IPF-Related Cough

Trial Objective

IPF-Related CoughThe purpose of this study is to evaluate the efficacy of an investigational study drug called RVT-1601 for treatment of persistent cough in patients with Idiopathic Pulmonary Fibrosis (IP) and to understand the impact on patients’ cough symptoms over time.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults over 40 years of age with IPF and persistent cough for a minimum of 8 weeks.

Age: 40-89    Gender: Any Gender

Estimated Time Commitment

12 clinic visits over 7 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kaitlin Fier

Kaitlin Fier

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Respivant Sciences


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.